Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Škof Erik) .

1 - 10 / 50
First pagePrevious page12345Next pageLast page
1.
2.
3.
Naše izkušnje s PARP inhibitorji pri raku jajčnikov na OI Ljubljana
Erik Škof, 2023, published scientific conference contribution

Keywords: rak jajčnikov, sistemsko zdravljenje, ginekološki raki
Published in DiRROS: 23.11.2023; Views: 179; Downloads: 101
.pdf Full text (340,15 KB)
This document has many files! More...

4.
Imunoterapija pri raku telesa maternice
Erik Škof, 2023, published scientific conference contribution

Abstract: Nova molekularna klasifikacija raka telesa maternice je omogočila novo, usmerjeno zdravljenje bolnic z rakom telesa maternice. Glavno novost predstavlja imunoterapija z zaviralci imunskih nadzornih točk (zaviralci PD-1) pri bolnicah z metastatskim rakom telesa maternice v 2. liniji zdravljenja, po predhodnem zdravljenu s kemoterapijo. Evropska agencija za zdravila (EMA) je odobrila uporabo dveh zaviralcev PD-1 receptorjev - dostarlimab in pembrolizumab v monoterapiji v primeru, da gre za okvaro MMR proteinov v tumorju (dMMR/MSI-H karcinom). Odobrena je tudi kombinacija pembrolizumaba in lenvatiniba (zaviralec tirozin kinaz) v 2. liniji zdravljenja metastatske bolezni, po predhodnem zdravljenju s kemoterapijo, ne glede na status MMR proteinov, torej tudi v primeru, da ne gre za okvaro MMR proteinov v tumorju (pMMR/MSS karcinom). Pred kratkim so bili objavljeni rezultati, ki kažejo učinkovitost pembrolizumaba in dostarlimaba v kombinaciji s kemoterapijo v 1. liniji napredovale ali metastatske bolezni. V adjuvantnem zdravljenju zaenkrat še nimamo podatkov o učinkovitosti imunoterapije - potekajo klinične raziskave.
Keywords: rak maternice, ginekološki raki, ginekološka onkologija
Published in DiRROS: 30.05.2023; Views: 292; Downloads: 114
.pdf Full text (281,13 KB)
This document has many files! More...

5.
Neželeni učinki sistemskega zdravljenja raka
Erik Škof, 2022, published scientific conference contribution

Abstract: Pri beleženju neželenih učinkov sistemskega zdravljenja uporabljamo mednarodne kriterije “Common Terminology Criteria for Adverse Events”, ki jih je ustanovil Ameriški Nacionalni inštitut za zdravljenje raka. V prispevku prikazujemo definicije izrazov, ki jih uporabljamo pri opisovanju in vrednotenju neželenih učinkov zdravljenja. Po Zakonu o zdravilih in Pravilniku o farmakovigilanci zdravil za uporabo v humani medicini je poročanje o domnevnih neželenih učinkih za zdravstvene delavce obvezno. Prikazujemo osnovna navodila in informacije za prijavo neželenih učinkov zdravljenja.
Keywords: neželeni učinki, bolniki, sistemsko zdravljenje
Published in DiRROS: 17.01.2023; Views: 377; Downloads: 99
.pdf Full text (69,50 KB)

6.
Intraperitonealna kemoterapija pri raku jajčnikov, za in proti
Erik Škof, 2022, published scientific conference contribution

Keywords: rak jajčnikov, rak jajcevodov, kemoterapija, onkološka ginekologija
Published in DiRROS: 04.01.2023; Views: 492; Downloads: 93
.pdf Full text (224,76 KB)

7.
Real-world data on detection of germline and somatic pathogenic/likely pathogenic variants in BRCA1/2 and other susceptibility genes in ovarian cancer patients using next generation sequencing
Vida Stegel, Ana Blatnik, Erik Škof, Vita Šetrajčič Dragoš, Mateja Krajc, Brigita Gregorčič, Petra Škerl, Ksenija Strojnik, Gašper Klančar, Marta Banjac, Janez Žgajnar, Maja Ravnik-Oblak, Srdjan Novaković, 2022, original scientific article

Abstract: Detection of germline and somatic pathogenic/likely pathogenic variants (PV/LPV) in BRCA genes is at the moment a prerequisite for use of PARP inhibitors in different treatment settings of different tumors. The aim of our study was to determine the most appropriate testing workflow in epithelial ovarian cancer (EOC) patients using germline and tumor genotyping of BRCA and other hereditary breast and/or ovarian cancer (HBOC) susceptibility genes. Consecutive patients with advanced non-mucinous EOC, who responded to platinum-based chemotherapy, were included in the study. DNA extracted from blood and FFPE tumor tissue were genotyped using NGS panels TruSightCancer/Hereditary and TruSight Tumor 170. Among 170 EOC patients, 21.8% had BRCA germline or somatic PV/LPV, and additionally 6.4% had PV/LPV in other HBOC genes. Sensitivity of tumor genotyping for detection of germline PV/LPV was 96.2% for BRCA genes and 93.3% for HBOC genes. With germline genotyping-only strategy, 58.8% of HBOC PV/LPV and 68.4% of BRCA PV/LPV were detected. By tumor genotyping-only strategy, 96.1% of HBOC PV/LPV and 97.4% of BRCA PV/LPV were detected. Genotyping of tumor first, followed by germline genotyping seems to be a reasonable approach for detection of PV/LPV in breast and/or ovarian cancer susceptibility genes in non-mucinous EOC patients.
Keywords: BRCA, ovarian cancer, tumor genotyping, HBOC
Published in DiRROS: 06.09.2022; Views: 482; Downloads: 265
.pdf Full text (2,35 MB)
This document has many files! More...

8.
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
Urška Janžič, Urška Bidovec, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čakš, Erik Škof, Jerneja Debeljak, Peter Korošec, Matija Rijavec, 2022, original scientific article

Abstract: Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
Keywords: onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer
Published in DiRROS: 24.06.2022; Views: 770; Downloads: 317
.pdf Full text (2,03 MB)

9.
10.
Analiza trenda napotitev na onkološko genetsko obravnavo pri bolnicah z rakom jajčnikov, ki potrebujejo genetski izvid za načrtovanje zdravljenja in predstavitev novih kliničnih poti obravnave
Svetlana Novak, Simona Hotujec, Ksenija Strojnik, Ana Blatnik, Erik Škof, Maja Ravnik-Oblak, Srdjan Novaković, Mateja Krajc, 2021, original scientific article

Abstract: Zadnjih nekaj let se v genetskih ambulantah soočamo s pogostejšimi napotitvami bolnikov z rakom na genetsko obravnavo. Izvid genetskega testiranja je namreč pri bolnicah z epitelijskim nemucinoznim rakom jajčnikov/jajcevodov/primarnim peritonealnim seroznim karcinomom (PPSC) in bolnikih z metastatskim rakom prostate/pankreasa/dojk lahko zelo pomemben za načrtovanje zdravljenja z zaviralci poli(ADP-riboza)-polimeraze (PARP). Ker se z obravnavo običajno mudi, smo izdelali dve klinični poti, ki omogočita tem bolnikom prednostno obravnavo.
Keywords: epitelijski nemucinozni rak jajčnikov, epitelijski nemucinozni rak jajcevodov, primarni peritonealni serozni karcinom/PPSC, prednostna napotitev, genetsko testiranje, BRCA1/2
Published in DiRROS: 13.12.2021; Views: 887; Downloads: 391
.pdf Full text (416,01 KB)
This document has many files! More...

Search done in 0.35 sec.
Back to top